Ulla Feldt-Rasmussen
Feldt-Rasmussen, Ulla
VIAF ID: 61498792 (Personal)
Permalink: http://viaf.org/viaf/61498792
Preferred Forms
- 100 1 _ ‡a Feldt-Rasmussen, Ulla
-
- 100 1 _ ‡a Feldt-Rasmussen, Ulla
- 100 1 _ ‡a Feldt-Rasmussen, Ulla
- 100 1 _ ‡a Feldt-Rasmussen, Ulla
-
- 100 0 _ ‡a Ulla Feldt-Rasmussen
4xx's: Alternate Name Forms (8)
Works
Title | Sources |
---|---|
GHD during critical phases of life : 6th KIGS/KIMS expert meeting on growth hormone and growth disorders, Florence, Italy, November 8-9, 2002 | |
Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing | |
Increase in thyroglobulin antibody and thyroid peroxidase antibody levels, but not preterm birth-rate, in pregnant Danish women upon iodine fortification | |
Increased risk of osteoporotic fractures in patients with Cushing's syndrome | |
Influence of phthalates on cytokine production in monocytes and macrophages: a systematic review of experimental trials | |
Influence of phthalates on in vitro innate and adaptive immune responses | |
Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment | |
Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions | |
Intrachiasmatic abscess caused by IgG4-related hypophysitis. | |
Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats | |
Isolated growth hormone | |
Less known aspects of central hypothyroidism: Part 2 - Congenital etiologies | |
Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY. | |
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. | |
[Measurement of health-related quality of life in thyroid patients] | |
[Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist] | |
Medicin | |
The metabolic consequences of thyroxine replacement in adult hypopituitary patients. | |
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. | |
Migration of phthalates on culture plates - an important challenge to consider for in vitro studies. | |
Mortality and GH deficiency: a nationwide study | |
Mortality in patients with Pheochromocytoma: a population-based study 1977-2016 | |
Narrow intra-individual variation of maternal thyroid function in pregnancy based on a longitudinal study on 132 women | |
New neoplasm during GH replacement in adults with pituitary deficiency following malignancy- a KIMS analysis | |
Obesity: the new worldwide epidemic threat to general health and our complete lack of effective treatment. | |
Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement | |
Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density | |
Overall and cause-specific mortality in GH-deficient adults on GH replacement. | |
Pathogenic role of interleukin 1 and tumor necrosis factor in autoimmune endocrine diseases | |
Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. | |
Phenotypic and genotypic features of a large kindred with a germline AIP variant | |
Pheochromocytoma in Denmark during 1977–2016: validating diagnosis codes and creating a national cohort using patterns of health registrations. | |
Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro | |
Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS database | |
PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. | |
Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up | |
Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: results from The Danish National Study on Posttraumatic Hypopituitarism. | |
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer | |
Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study | |
Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population. | |
Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram v | |
Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. | |
Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease | |
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. | |
Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage | |
Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study | |
Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. | |
Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency | |
Risk of Thyroid Cancer in 1,504 Patients Referred for Thyroid Surgery with Assumed Benign Histology | |
Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. | |
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study | |
Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial | |
Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism. | |
Serum levels of activin A and inhibin A are not related to the increased susceptibility to pre-eclampsia in type I diabetic pregnancies | |
Serum thyroglobulin and thyroglobulin autoantibodies in thyroid diseases : pathogenic and diagnostic aspects | |
Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature | |
Shorter Recall Period for the Thyroid-Related Patient-Reported Outcome Measure ThyPRO Did Not Change the Accuracy as Evaluated by Repeated Momentary Measurements | |
Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment | |
Signs of maternal vascular dysfunction precede preeclampsia in women with type 1 diabetes | |
Similar clinical features among patients with severe adult growth hormone deficiency diagnosed with insulin tolerance test or arginine or glucagon stimulation tests. | |
Sleep-wake and melatonin pattern in craniopharyngioma patients. | |
Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin | |
Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study | |
Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. | |
ThyPROgr: the Greek edition of the ThyPRO questionnaires for patients with benign thyroid diseases | |
Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper | |
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. | |
Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. | |
Thyroid effects of endocrine disrupting chemicals. | |
Thyroid function and autoimmunity in Danish pregnant women after an iodine fortification program and associations with obstetric outcomes | |
Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss | |
Thyroid-specific questions on work ability showed known-groups validity among Danes with thyroid diseases | |
Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology | |
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. | |
Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache | |
Ultrasonically measured horizontal eye muscle thickness in thyroid associated orbitopathy: cross‐sectional and longitudinal aspects in a Danish series | |
Unsuccessful radioiodine treatment of a non-toxic goiter: a case report | |
Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. | |
Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself |